Why is it that we can put a man on the Moon, but we can’t figure out how to screen jet passengers without making everyone take their shoes off?
Well, the truth is, we can’t even put a man on the... Read more »
Changes in the transportation sector are happening pretty fast these days, spurred by the wide availability of smartphones and richly funded startups with a new take on old-school taxi and car rental services.
That’s meant clashes with local regulators, established... Read more »
Aereo’s legal war ended in the chambers of the U.S. Supreme Court, but other startups should be wary.
In spite of CEO Chet Kanojia’s audacity, on Wednesday the New York-based company that thought it could trump television broadcasters lost its closely... Read more »
Rachel King is CEO of GlycoMimetics (NASDAQ: GLYC), a Gaithersburg, MD-based drug developer, and the current chairwoman of the Biotechnology Industry Organization.
As a heavily regulated industry, biopharma’s interactions with politicians and policy makers are crucial, and BIO has grown... Read more »
A new San Diego biotech, led by former Trius Therapeutics CEO Jeff Stein, has raised over $30 million to advance new drugs to treat life-threatening invasive fungal infections, according to a recent regulatory filing.
Stein declined to discuss the financing by... Read more »
It’s a busy news week for established tech companies around here—see Aereo, Imprivata—but let’s take a look at the other side of the market: the early-stage startups.
For all the talk of a Series A crunch and the limited... Read more »
The Boston-area tech industry saw another company graduate to the public markets on Wednesday with Imprivata’s IPO, which netted the healthcare software provider an estimated $66.3 million.
Imprivata shares (NYSE: IMPR) traded slightly higher in early market activity, which... Read more »